

Santen Announces Change of Representative Director of the Board and Board of Director and Corporate Auditor Nominations

Santen Pharmaceutical Co., Ltd. (Head Office: Osaka; President and CEO: Shigeo Taniuchi: hereafter “Santen” or “Company”) today announced that its Board of Directors has approved the following management changes and the nominations for the members of the Board of Directors and Corporate Auditors as described below. This change becomes effective June 24, 2022, subject to approval at the 110th Annual General Meeting of Shareholders and the following Board of Directors meeting on June 24, 2022.

1. Change of Representative Director of the Board

(1) Reason for change

Strengthening the Board's holistic execution capabilities in light of a severe business environment

(2) Details of the change

Name	Newly Appointed	Current Position
Akira Kurokawa	Representative Director of the Board, Chairman	Director of the Board, Chairman

(3) Profile of the New Representative Director of the Board, Chairman

Name Akira Kurokawa
Number of Shares held 200,060 (as of March, 2022)

Profile

April 1977	Joined the Company
April 1997	General Manager, Head of the Office of Sales & Marketing Division, Prescription Pharmaceuticals
June 1997	Director
June 1998	Deputy Head of Sales & Marketing Division, Prescription Pharmaceuticals
May 2001	Head of Sales & Marketing Division, Prescription Pharmaceuticals
June 2001	Corporate Officer
July 2004	Senior Corporate Officer
June 2006	Representative Director, President & COO
June 2008	Representative Director, President & CEO
April 2018	Representative Director, Chairman & CEO
April 2020	Representative Director, Chairman
April 2022	Director, Chairman (incumbent)

(4) Timing of implementation

June 24, 2022

2. Nominations for the members of the Board of Directors and Corporate Auditors (As of June 24, 2022)

[Directors]

	Name	New position	Current position
Reappointed	Akira Kurokawa	Representative Director of the Board, Chairman	Director of the Board, Chairman
	Shigeo Taniuchi	Representative Director of the Board, President, Chief Executive Officer	Representative Director of the Board, President, Chief Executive Officer
	Takeshi Ito	Representative Director of the Board, Executive Vice President, Head of Japan Business, Head of Japan Sales and Marketing Division	Representative Director of the Board, Executive Vice President, Head of Japan Business, Head of Japan Sales and Marketing Division
	Kanoko Oishi	Director of the Board*	Director of the Board*
	Yutaro Shintaku	Director of the Board*	Director of the Board*
	Kunihito Minakawa	Director of the Board*	Director of the Board*
Newly appointed	Noboru Kotani	Director of the Board*	---
	Tamie Minami	Director of the Board*	---

*Outside Directors are independent officers in accordance with the Tokyo Stock Exchange regulations

[Corporate Auditors]

	Name	New position	Current position
Newly appointed	Masahiko Ikaga	Corporate Auditor**	---
Retirement	Yasuyuki Miyasaka	---	Corporate Auditor**

**Outside Corporate Auditors are independent officers designated by the Tokyo Stock Exchange.

Other Auditors (Hiroshi Isaka, Hirofumi Yasuhara and Yumiko Ito) are within their term of office and, therefore, not subject to reelection this year.

Contact:

Guillaume Sakuma

Global Head of IR, IR Group

E-mail: ir@santen.com

About Santen

As a specialized company dedicated to ophthalmology, Santen carries out research, development, marketing, and sales of pharmaceuticals, over-the-counter products, and medical devices, and its products now reach patients in over 60 countries.

Toward realizing “WORLD VISION” (Happiness with Vision), the world Santen ultimately aspires to achieve, as a “Social Innovator”, we aim to reduce the social and economic opportunity loss of people around the world caused by eye diseases and defects by orchestrating and mobilizing key technologies and players around the world.

With scientific knowledge and organizational capabilities nurtured over a 130-year history, Santen provides products and services to contribute to the well-being of patients, their loved ones and consequently to society.

For more information, please visit Santen’s website (<https://www.santen.com/en/>).